Format

Send to

Choose Destination
Expert Rev Mol Diagn. 2015;15(11):1427-40. doi: 10.1586/14737159.2015.1094379. Epub 2015 Sep 30.

Emerging platforms using liquid biopsy to detect EGFR mutations in lung cancer.

Author information

1
a 1 Department of Internal Medicine, Institute of Clinical Medicine, National Cheng Kung University, Hospital, College of Medicine , Tainan, Taiwan.
2
b 2 UCLA - Dentistry, 73-034 CHS UCLA School of Dentistry , 10833 Le Conte Avenue, Los Angeles, California 90095, USA.

Abstract

Advances in target therapies for lung cancer have enabled detection of gene mutations, specifically those of EGFR. Assays largely depend on the acquisition of tumor tissue biopsy, which is invasive and may not reflect the genomic profile of the tumor at treatment due to tumor heterogeneity or changes that occur during treatment through acquired resistance. Liquid biopsy, a blood test that detects evidence of cancer cells or tumor DNA, has generated considerable interest for its ability to detect EGFR mutations. However, its clinical application is limited by complicated collection methods and the need for technique-dependent platforms. Recently, simpler techniques for EGFR mutant detection in urine or saliva samples have been developed. This review focuses on advances in liquid biopsy and discusses its potential for clinical implementation in lung cancer.

KEYWORDS:

epidermal growth factor receptor; liquid biopsy; lung cancer; saliva; target therapy

PMID:
26420338
PMCID:
PMC4889428
DOI:
10.1586/14737159.2015.1094379
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center